154 related articles for article (PubMed ID: 34620694)
21. Statin Drug-Drug Interactions: Pharmacokinetic Basis of FDA Labeling Recommendations and Comparison Across Common Tertiary Clinical Resources.
Mease J; Ramamoorthy A; Yang X; Madabushi R; Pfuma Fletcher E; Zineh I
J Clin Pharmacol; 2024 Jun; 64(6):704-712. PubMed ID: 38299698
[TBL] [Abstract][Full Text] [Related]
22. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
[TBL] [Abstract][Full Text] [Related]
23. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
24. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of US Food and Drug Administration Drug Label Recommendations for Coadministration of Antivirals and Acid-Reducing Agents.
Shugg T; Powell NR; Marroum PJ; Skaar TC; Younis IR
